These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 3088346)

  • 41. Antibacterial activity of tigemonam dicholate (SQ 30836) and interaction with beta-lactamases of gram-negative bacteria.
    Raimondi A; Cocuzza CE
    J Chemother; 1989 May; 1 Suppl 2():13-21. PubMed ID: 2809698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Susceptibility of clinically isolated strains to aztreonam].
    Daimon Y
    Jpn J Antibiot; 1988 Nov; 41(11):1623-34. PubMed ID: 3145344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Apr; 55(2):154-80. PubMed ID: 12071094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide.
    Viljanen P; Vaara M
    Antimicrob Agents Chemother; 1984 Jun; 25(6):701-5. PubMed ID: 6331296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC; Chin NX; Jules K; Labthavikul P
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Susceptibility of clinical bacterial isolates to aztreonam].
    Murase M; Niiya T; Takeuchi N
    Jpn J Antibiot; 1987 Sep; 40(9):1698-706. PubMed ID: 3121888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro antimicrobial activity of a novel aminothiazolylglycylcephalosporin, MT0703S, compared with that of ceftazidime, cefoperazone and aztreonam.
    Okamoto R; Hara T; Yoshida T; Orikasa Y; Ogino H; Iwamatsu K; Inouye S
    Drugs Exp Clin Res; 1990; 16(4):157-65. PubMed ID: 2127567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How and why aztreonam works.
    Rittenbury MS
    Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
    Chong Y; Lee K; Kwon OH
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():21-9. PubMed ID: 8150765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative in vitro activity of carumonam (Ro 17-2301/AMA-1080), a new monobactam, and ceftriaxone against aerobic or facultative gram-negative isolates.
    Barclay CA; Iribarren MA; Goldberg M; Traballi CA; Casellas JM
    Chemotherapy; 1987; 33(3):165-71. PubMed ID: 3595259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Reported by the Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1990 Nov; 43(11):1956-2002. PubMed ID: 2287060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vitro anti-microbial susceptibility of clinical isolates of pathogenic bacteria to ten antibiotics including phosphomycin.
    Eke PI; Rotimi VO
    Afr J Med Med Sci; 1987 Mar; 16(1):1-8. PubMed ID: 3037870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tigemonam, an oral monobactam.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1988 Jan; 32(1):84-91. PubMed ID: 3279906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibacterial activity of BMS-180680, a new catechol-containing monobactam.
    Fung-Tomc J; Bush K; Minassian B; Kolek B; Flamm R; Gradelski E; Bonner D
    Antimicrob Agents Chemother; 1997 May; 41(5):1010-6. PubMed ID: 9145861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates.
    Fuchs PC; Gavan TL; Gerlach EH; Jones RN; Barry AL; Thornsberry C
    Am J Med Sci; 1977; 274(3):255-63. PubMed ID: 610415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The in vitro activity of ciprofloxacin against clinically-isolated strains of Pseudomonas aeruginosa and comparison with some other antibiotics].
    Sener B; Hayran M; Kocagöz T; Ustaçelebi S
    Mikrobiyol Bul; 1990 Apr; 24(2):120-5. PubMed ID: 2128529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In Vitro Activity of Tigemonam Against Urinary Tract Pathogens.
    Garcia-Rodriguez JA; Garcia-Sanchez JE
    J Chemother; 1989 May; 1(sup2):28-31. PubMed ID: 27416146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.
    Ducan IB; Penner JL
    Can Med Assoc J; 1975 Jul; 113(1):29-31. PubMed ID: 807310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1990 Oct; 43(10):1723-82. PubMed ID: 2086814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of tigemonam against multiresistant nosocomial Enterobacteriaceae.
    Giamarellou H; Pephanis A; Grammatikou M; Avlamis A; Papoulias G
    J Chemother; 1989 May; 1 Suppl 2():32-5. PubMed ID: 2809700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.